Literature DB >> 32016024

Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy.

Chiara Napoletano1, Filippo Bellati2.   

Abstract

Entities:  

Year:  2019        PMID： 32016024      PMCID： PMC6976393          DOI： 10.21037/atm.2019.10.62

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

2.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

Authors:  Wei-Ting Hwang; Sarah F Adams; Emin Tahirovic; Ian S Hagemann; George Coukos
Journal:  Gynecol Oncol       Date:  2011-10-29       Impact factor: 5.482

Review 3.  The development and use of vascular targeted therapy in ovarian cancer.

Authors:  Dana M Chase; David J Chaplin; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2017-02-24       Impact factor: 5.482

4.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 5.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

Review 6.  Neoantigens in cancer immunotherapy.

Authors:  Ton N Schumacher; Robert D Schreiber
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

7.  Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.

Authors:  Morena Antonilli; Hassan Rahimi; Valeria Visconti; Chiara Napoletano; Ilary Ruscito; Ilaria Grazia Zizzari; Salvatore Caponnetto; Giacomo Barchiesi; Roberta Iadarola; Luca Pierelli; Aurelia Rughetti; Filippo Bellati; Pierluigi Benedetti Panici; Marianna Nuti
Journal:  Int J Oncol       Date:  2016-02-08       Impact factor: 5.650

Review 8.  Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.

Authors:  Yu Shen Wu; Lin Shui; Dan Shen; Xiaopin Chen
Journal:  Oncotarget       Date:  2017-02-07

9.  Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.

Authors:  Chiara Napoletano; Ilary Ruscito; Filippo Bellati; Ilaria Grazia Zizzari; Hassan Rahimi; Maria Luisa Gasparri; Morena Antonilli; Pierluigi Benedetti Panici; Aurelia Rughetti; Marianna Nuti
Journal:  J Clin Med       Date:  2019-03-18       Impact factor: 4.241

10.  Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

Authors:  Song Liu; Junko Matsuzaki; Lei Wei; Takemasa Tsuji; Sebastiano Battaglia; Qiang Hu; Eduardo Cortes; Laiping Wong; Li Yan; Mark Long; Anthony Miliotto; Nicholas W Bateman; Shashikant B Lele; Thinle Chodon; Richard C Koya; Song Yao; Qianqian Zhu; Thomas P Conrads; Jianmin Wang; George L Maxwell; Amit A Lugade; Kunle Odunsi
Journal:  J Immunother Cancer       Date:  2019-06-20       Impact factor: 12.469
View more
  1 in total

1.  Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer.

Authors:  Tao Jiang; Ruirui Cheng; Yuanwei Pan; Henghui Zhang; Ying He; Chunxia Su; Shengxiang Ren; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2020-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.